Information  X 
Enter a valid email address

Company Name matching 'Galapagos NV'

Date
Time Source
Company
Announcement
06 May 2021 9:01 pm GNW   Galapagos NV Galapagos refocuses pipeline and rightsizes operations  
04 May 2021 9:01 pm GNW   Galapagos NV Transparency notification received from The Capital Group
30 Apr 2021 9:01 pm GNW   Galapagos NV Galapagos creates new subscription right plans
23 Apr 2021 5:01 am GNW   Galapagos NV Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies
08 Apr 2021 9:01 pm GNW   Galapagos NV Extension of lock-up period in Gilead-Galapagos collaboration agreement
25 Mar 2021 8:01 pm GNW   Galapagos NV Publication of the annual report and invitation to the ordinary shareholders’ meeting
24 Mar 2021 8:01 pm GNW   Galapagos NV Galapagos appoints Bart Filius as President and Chief Operating Officer
19 Mar 2021 9:01 pm GNW   Galapagos NV Galapagos increases share capital through subscription right exercises
04 Mar 2021 6:49 am GNW Factsheet Galapagos NV (GLPG) GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES
03 Mar 2021 9:15 pm GNW Factsheet Galapagos NV (GLPG) Transparency notification received from The Capital Group
18 Feb 2021 9:01 pm GNW Factsheet Galapagos NV (GLPG) Pipeline and capital for growth
10 Feb 2021 2:00 pm GNW Factsheet Galapagos NV (GLPG) Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
09 Feb 2021 9:01 pm GNW Factsheet Galapagos NV (GLPG) The Capital Group holds 10.03% of Galapagos shares
21 Jan 2021 7:08 am GNW Factsheet Galapagos NV (GLPG) NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis
11 Jan 2021 9:01 pm GNW Factsheet Galapagos NV (GLPG) Gilead holds 25.54% of Galapagos shares
06 Jan 2021 2:30 pm GNW Factsheet Galapagos NV (GLPG) Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference
04 Jan 2021 9:01 pm GNW Factsheet Galapagos NV (GLPG) Selvita completes acquisition of Fidelta from Galapagos
23 Dec 2020 5:00 pm GNW Factsheet Galapagos NV (GLPG) Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks
15 Dec 2020 9:15 pm GNW Factsheet Galapagos NV (GLPG) Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  Jyseleca® (filgotinib)  
04 Dec 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through subscription right exercises
01 Dec 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
30 Nov 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial 
23 Nov 2020 9:15 pm GNW Factsheet Galapagos NV (GLPG) Selvita to acquire Fidelta from Galapagos
09 Nov 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
05 Nov 2020 9:15 pm GNW Factsheet Galapagos NV (GLPG) OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis
  9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos reports Q3 2020 results
02 Nov 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) EUROPEAN  MEDICINES  AGENCY  VALIDATES  MARKETING  APPLICATION  FOR  FILGOTINIB  FOR  THE  TREATMENT  OF  ULCERATIVE  COLITIS
27 Oct 2020 3:20 pm GNW Factsheet Galapagos NV (GLPG) Galapagos’ R&D Roundtable showcases Toledo program
15 Oct 2020 9:19 pm GNW Factsheet Galapagos NV (GLPG) Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
12 Oct 2020 2:15 pm GNW Factsheet Galapagos NV (GLPG) PHASE 2B/3 TRIAL SHOWS EFFICACY OF FILGOTINIB FOR THE INDUCTION AND MAINTENANCE OF REMISSION IN MODERATELY AND SEVERELY ACTIVE ULCERATIVE COLITIS
29 Sep 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial
25 Sep 2020 6:00 pm GNW Factsheet Galapagos NV (GLPG) EUROPEAN  COMMISSION  GRANTS  MARKETING  AUTHORIZATION FOR JYSELECA®(FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO  SEVERE ACTIVE  RHEUMATHOID  ARTHRITIS
  7:13 am GNW Factsheet Galapagos NV (GLPG) Correction: Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
18 Sep 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through subscription right exercises
11 Sep 2020 3:30 am GNW Factsheet Galapagos NV (GLPG) Primary endpoint achieved with ziritaxestat  in NOVESA trial in systemic sclerosis patients
26 Aug 2020 6:30 am GNW Factsheet Galapagos NV (GLPG) Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society Congress   
19 Aug 2020 12:25 am GNW Factsheet Galapagos NV (GLPG) Galapagos announces that Gilead received a complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis
12 Aug 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease
06 Aug 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos reports solid H1 2020 progress
24 Jul 2020 1:14 pm GNW Factsheet Galapagos NV (GLPG) GILEAD  AND  GALAPAGOS  ANNOUNCE  POSITIVE  EUROPEAN  CHMP  OPINION  FOR  JYSELECA® (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO  SEVERE  RHEUMATOID  ARTHRITIS
05 Jun 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) NEW ANALYSES OF PHASE 2 EQUATOR CLINICAL PROGRAM SUPPORT DURABLE EFFICACY OF FILGOTINIB IN PSORIATIC ARTHRITIS
04 Jun 2020 6:00 am GNW Factsheet Galapagos NV (GLPG) FILGOTINIB DEMONSTRATES DURABLE EFFICACY AND CONSISTENT SAFETY PROFILE AT 52 WEEKS IN FINCH 1 AND 3 STUDIES IN RHEUMATOID ARTHRITIS
28 May 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through subscription right exercises
20 May 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) GILEAD AND GALAPAGOS ANNOUNCE POSITIVE TOPLINE RESULTS OF PHASE 2B/3 TRIAL OF FILGOTINIB IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
07 May 2020 9:03 pm GNW Factsheet Galapagos NV (GLPG) On track for clinical read-outs and commercial readiness in 2020
17 Apr 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos creates new subscription right plans
  12:04 am GNW Factsheet Galapagos NV (GLPG) Important update to Galapagos’ invitation to its ordinary and extraordinary shareholders’ meetings
16 Apr 2020 6:30 am GNW Factsheet Galapagos NV (GLPG) Galapagos and Ryvu announce research collaboration
27 Mar 2020 8:01 pm GNW Factsheet Galapagos NV (GLPG) Publication of the annual report and invitation to the ordinary and extraordinary shareholders’ meetings
17 Mar 2020 8:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises
20 Feb 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Transformational year for Galapagos
29 Jan 2020 7:00 am GNW Factsheet Galapagos NV (GLPG) Orphan Drug Designation for GLPG1690 in systemic sclerosis
23 Jan 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos appoints Michele Manto as Chief Commercial Officer
15 Jan 2020 6:30 am GNW Factsheet Galapagos NV (GLPG) Fibrocor and Galapagos sign expanded collaboration in fibrosis
13 Jan 2020 6:30 am GNW Factsheet Galapagos NV (GLPG) Galapagos completes recruitment of PINTA trial in idiopathic pulmonary fibrosis
09 Jan 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos to present at 38th Annual J.P. Morgan Healthcare Conference
  9:01 pm GNW Factsheet Galapagos NV (GLPG) Gilead holds 25.84% of Galapagos shares
19 Dec 2019 9:30 pm GNW Factsheet Galapagos NV (GLPG) Gilead submits new drug application to U.S. Food and Drug Administration under priority review for filgotinib for rheumatoid arthritis treatment
05 Dec 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos completes recruitment of NOVESA trial in systemic sclerosis
25 Nov 2019 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through warrant exercises


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t